Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Preferred Stock Liabilities (2016)

Voyager Therapeutics (VYGR) has disclosed Preferred Stock Liabilities for 2 consecutive years, with $36.1 million as the latest value for Q4 2016.

  • Quarterly Preferred Stock Liabilities changed 0.13% to $36.1 million in Q4 2016 from the year-ago period, while the trailing twelve-month figure was $36.1 million through Dec 2016, changed 0.13% year-over-year, with the annual reading at $36.1 million for FY2016, 0.13% changed from the prior year.
  • Preferred Stock Liabilities hit $36.1 million in Q4 2016 for Voyager Therapeutics, roughly flat from $36.1 million in the prior quarter.
  • In the past five years, Preferred Stock Liabilities ranged from a high of $59.9 million in Q3 2015 to a low of $36.1 million in Q4 2015.